<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068780</url>
  </required_header>
  <id_info>
    <org_study_id>BEB-13</org_study_id>
    <secondary_id>2016-002066-32</secondary_id>
    <nct_id>NCT03068780</nct_id>
  </id_info>
  <brief_title>Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa</brief_title>
  <acronym>EASE</acronym>
  <official_title>Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amryt Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amryt Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited&#xD;
      Epidermolysis Bullosa (EB).&#xD;
&#xD;
      EB is a rare group of genetic skin fragility disorders characterised by blistering of the&#xD;
      skin in response to minor injury. In most cases, onset of EB is at birth or shortly after.&#xD;
      All participants affected by any type of EB share the main characteristic of repeatedly&#xD;
      developing painful wounds that take days to months to heal. Current treatment of EB is&#xD;
      primarily preventative and supportive including protection from mechanical forces by avoiding&#xD;
      rubbing, early treatment of wounds to prevent infections, and protection of the wound with&#xD;
      adequate non-adhesive dressings to enable healing.&#xD;
&#xD;
      Oleogel-S10 was authorised in 2016 in the European Union for treatment of partial thickness&#xD;
      wounds in adults under the brand name Episalvan®. The active pharmaceutical ingredient in&#xD;
      Oleogel-S10 is a refined birch bark extract, quantified to 72 to 88% betulin.&#xD;
&#xD;
      This clinical study of Oleogel-S10 in patients with inherited EB has been initiated to&#xD;
      investigate whether Oleogel-S10 is effective for treatment of EB wounds and safe in the long&#xD;
      term use.&#xD;
&#xD;
      Oleogel-S10 will be compared to a vehicle gel placebo. The placebo is an identical looking&#xD;
      sunflower oil gel that does not contain any active substance. The participant will receive&#xD;
      either Oleogel-S10 or vehicle gel for a double-blind study phase of 90 days. The probability&#xD;
      that the participant will receive Oleogel-S10 is 50%, which means that they have a 1 in 2&#xD;
      chance of receiving Oleogel-S10. However, in the follow-up phase of the study all&#xD;
      participants will be treated with Oleogel S10 for a period of 24 months.&#xD;
&#xD;
      This clinical study will be performed in several countries; in total, about 250 participants&#xD;
      are expected to participate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">June 11, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with first complete closure of the EB target wound within 45 days of treatment</measure>
    <time_frame>45±7 days</time_frame>
    <description>Proportion of patients with first complete closure of the EB target wound (defined as EB partial thickness wound of 10 cm2 to 50 cm2 in size aged ≥ 21 days and &lt; 9 months) in patients with inherited EB (subtypes JEB, DEB, or Kindler syndrome) within 45±7 days of treatment with Oleogel S10 compared to vehicle based on clinical assessment by the investigator (the wound will be rated as &quot;closed&quot; at first appearance of complete reepithelialisation without drainage)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first complete closure of the EB target wound as evidenced by clinical assessment until EDBP (D90±7)</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with first complete closure of the EB target wound at D90±7 based on clinical assessment by the investigator until Day 90±7.</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of wound infection between baseline (DBP D0) and D90±7 as evidenced by AEs and/or use of topical and/or systemic antibiotics (related to wound infection)</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum severity of wound infection between baseline (DBP D0) and D90±7 as evidenced by AEs and/or use of topical and/or systemic antibiotics (related to wound infection)</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (DBP D0) in total body wound burden as evidenced by clinical assessment using Section I (assessment of the skin except for the anogenital region) of the 'EB Disease Activity and Scarring Index' (EBDASI) at D90±7</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (DBP D0) in itching using the 'Itch Man Scale' in patients ≥ 4 years and up to 13 years of age and the 'Leuven Itch Scale' in patients ≥ 14 years of age before wound dressing changes at D90±7</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Oleogel-S10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleogel-S10</intervention_name>
    <description>10% birch bark extract in 90% sunflower oil</description>
    <arm_group_label>Oleogel-S10</arm_group_label>
    <other_name>Episalvan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sunflower oil gel</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with the following subtypes of inherited EB: junctional EB&#xD;
             (JEB), dystrophic EB (DEB), and Kindler syndrome aged ≥21 days,&#xD;
&#xD;
          -  Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm²&#xD;
             in size aged ≥21 days and &lt;9 months),&#xD;
&#xD;
          -  Patient and/or his/her legal representative has/have been informed, has/have read and&#xD;
             understood the patient information/informed consent form, and has/have given written&#xD;
             informed consent,&#xD;
&#xD;
          -  Patient and/or his/her legal representative must be able and willing to follow study&#xD;
             procedures and instructions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has EB simplex&#xD;
&#xD;
          -  EB target wound with clinical signs of local infection,&#xD;
&#xD;
          -  Use of systemic antibiotics for wound-related infections within 7 days prior to&#xD;
             enrolment,&#xD;
&#xD;
          -  Administration of systemic or topical steroids (except for inhaled, ophthalmic or&#xD;
             topical applications, such as budesonide suspension for oesophageal strictures [e.g.,&#xD;
             Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL]) within 30 days before enrolment,&#xD;
&#xD;
          -  Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment,&#xD;
&#xD;
          -  Patient has undergone stem cell transplant or gene therapy for the treatment of&#xD;
             inherited EB,&#xD;
&#xD;
          -  Current and/or former malignancy including basal cell carcinomas and squamous cell&#xD;
             carcinomas,&#xD;
&#xD;
          -  Enrolment in any interventional study or treated with any investigational drug for any&#xD;
             disease within 4 weeks prior to study entry,&#xD;
&#xD;
          -  Factors present in the patient and/or his/her legal representative that could&#xD;
             interfere with study compliance such as inability to attend scheduled study visits or&#xD;
             compliance with home dressing changes,&#xD;
&#xD;
          -  Pregnant or nursing women and women of childbearing potential including postmenarchal&#xD;
             female adolescents not willing to use an effective form of birth control with failure&#xD;
             rates &lt;1% per year (e.g., implant, injectable, combined oral contraceptive,&#xD;
             intrauterine contraceptive device, sexual abstinence, vasectomised partner) during&#xD;
             participation in the study (and at least 3 months thereafter),&#xD;
&#xD;
          -  Patient is a member of the investigational team or his/her immediate family,&#xD;
&#xD;
          -  Patient lives in the same household as a study participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes S Kern, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amjad Plastic Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consutorios Medicos (Instituto de Neumonologia y Dermatologia)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Dra. De Salvo</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de investigaciones Metabolicas, CINME</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Specialists</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3502</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Dermatologie</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIP</name>
      <address>
        <city>Recife</city>
        <state>Pernanbuco</state>
        <zip>50070550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Regional de Blumenau</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <zip>89020400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Da Crianca HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403.000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Debra Chile</name>
      <address>
        <city>Santiago</city>
        <zip>7760099</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De San Jose</name>
      <address>
        <city>Bogotá</city>
        <state>DC</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno, Children´s Hospital</name>
      <address>
        <city>Brno</city>
        <zip>61500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hospital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S/R National Center of Dermatology and Venerology</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University Freiburg</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendkrankenhaus AUF DER BULT</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Skin and Veneral Diseases &quot;A. Syggros&quot;</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Faculty of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Ladys Childrens Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesù Children Hospital</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Dermopatico dell'Immacolata IDI-IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Sanador</name>
      <address>
        <city>Bucharest</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Scientific Center for Dermatovenerology and Cosmetology</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Center of Children's Health</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Belgrade, School of Medicine</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kandang Kerbau (KK) Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Viamed Santa Ángela de la Cruz</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Children Specialized Hospital &quot;Ohmatdyt&quot; of Ministry of Health of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Croatia</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

